Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined. Here, we perform single cell genomic characterization of longitudinal sa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Samur, Mehmet Kemal, Fulciniti, Mariateresa, Aktas Samur, Anil, Bazarbachi, Abdul Hamid, Tai, Yu-Tzu, Prabhala, Rao, Alonso, Alejandro, Sperling, Adam S., Campbell, Timothy, Petrocca, Fabio, Hege, Kristen, Kaiser, Shari, Loiseau, Hervé Avet, Anderson, Kenneth C., Munshi, Nikhil C.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7870932/
https://ncbi.nlm.nih.gov/pubmed/33558511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-21177-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars